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A B S T R A C T
Activated platelets generate an eicosanoid proposed to be 8-hydroxy-9,10-dioxolane A3 (DXA3). Herein, we
demonstrate that signiﬁcant amounts of DXA3 are rapidly attached to phosphatidylethanolamine (PE) forming
four esteriﬁed eicosanoids, 16:0p, 18:0p, 18:1p and 18:0a/DXA3-PEs that can activate neutrophil integrin
expression. These lipids comprise the majority of DXA3 generated by platelets, are formed in ng amounts (24.3
± 6.1 ng/2×108) and remain membrane bound. Pharmacological studies revealed DXA3-PE formation involves
cyclooxygenase-1 (COX), protease-activated receptors (PAR) 1 and 4, cytosolic phospholipase A2 (cPLA2),
phospholipase C and intracellular calcium. They are generated primarily via esteriﬁcation of newly formed
DXA3, but can also be formed in vitro via co-oxidation of PE during COX-1 co-oxidation of arachidonate. All
four DXA3-PEs were detected in human clots. Puriﬁed platelet DXA3-PE activated neutrophil Mac-1 expression,
independently of its hydrolysis to the free eicosanoid. This study demonstrates the structures and cellular
synthetic pathway for a family of leukocyte-activating platelet phospholipids generated on acute activation,
adding to the growing evidence that enzymatic PE oxidation is a physiological event in innate immune cells.
1. Introduction
Platelets generate eicosanoids including thromboxane A2 (TXA2),
12-hydroxyeicosatetraenoic acid (12-HETE), and small amounts of
prostaglandins (PGs), PGE2, and D2. We recently described a new
platelet eicosanoid, proposed to be 8-hydroxy-9,11-dioxolane eicosate-
traenoic acid (DXA3) [1]. Full structural characterization of this lipid
remains to be completed once we have suﬃcient quantities puriﬁed
from platelets or COX reactions. Importantly, we found that DXA3 both
primes and activates human neutrophils at nM-μM concentrations [1].
Platelets also form enzymatically-oxidized phospholipids (eoxPL)
that contain PGs or HETEs at the sn2 position [2,3]. These generally
comprise phosphatidylethanolamines (PE) with 16:0p, 18:1p, 18:0p or
18:0a predominating at sn1. We recently showed that thrombin-
activated platelets generate over 100 diverse eoxPL on acute activation
of platelets, including n3 and n6 fatty acids, and both single and
multiply oxygenated forms at sn2 [4]. This indicated that eoxPL
formation is a rapid and wide-ranging process of importance to innate
immunity. In support, HETE-PEs can modulate a number of relevant
events in vitro including enhancing clotting factor activities, modulat-
ing monocyte cytokine generation and enhancing neutrophil antibac-
terial actions [3,5,6]. Furthermore, two recent studies have shown a
critical role for these lipids in mediating ferroptotic cell death [7,8].
Herein, we describe the detailed cellular and enzymatic biosynth-
esis pathways for four PE-esteriﬁed forms of DXA3. A co-ordinated
series of enzymes and signaling mediators are required, including the
fast esteriﬁcation of newly formed DXA3 free acid. A quantitative assay
showed the majority of platelet DXA3 generated on thrombin activation
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is PE-esteriﬁed. DXA3-PEs remain cell associated, are detected in
human clots and activate neutrophil integrin expression, independently
of their hydrolysis to the free acid analog. In summary, DXA3-PEs are
platelet-derived lipids that can activate neutrophils adding to the
growing evidence for enzymatic phospholipid oxidation as a physiolo-
gical process of importance during early innate immunity.
2. Materials and methods
2.1. Materials
Lipids and lipid standards were purchased from Avanti Polar Lipids
(Alabaster, Alabama) or Cayman Chemical (Ann Arbor, Michigan).
Deuterated standards are as follows: PGE2-d4: 9-oxo-11α,15S-dihy-
droxy-prosta-5Z,13E-dien-1-oic-3,3,4,4-d4 acid, ≥99% deuterated
forms. HPLC grade solvents were from Thermo Fisher Scientiﬁc
(Hemel Hempstead, Hertfordshire UK). PAR-1 and −4 agonists and
U73112, U73343 were from Tocris Biosciences (Bristol, UK). COX-1
inhibitor (Sc-560) was from Cayman Chemical. Platelet signaling
inhibitors (oleyloxyethylphosphocholine (OOEPC), bromoenol lactone
(BEL), cytosolic phospholipase A2α (cPLA2α) inhibitor (N-((2S,4R)−4-
(Biphenyl-2-ylmethyl-isobutyl-amino)-1-[2-(2,4-diﬂuorobenzoyl)-ben-
zoyl]-pyrrolidin-2-ylmethyl}-3-[4-(2,4-dioxothiazolidin-5-ylidene-
methyl)-phenyl]acrylamide, HCl), Gö 6850 and wortmannin were from
Calbiochem (UK). All other reagents were from Sigma-Aldrich unless
otherwise stated. Ovine COX-1 was from Cayman Chemical or puriﬁed
as described [9,10].
2.2. Oxidation of phospholipid-esteriﬁed arachidonate by puriﬁed
COX-1
Apo-COX-1 was stored in 80 mM Tris, pH 7.8, at −80 °C. For heme
reconstitution, Apo-COX-1 (35 µg) was preincubated on ice for 20 min
with 2 M equivalents of hematin in phosphate buﬀer (100 mM
potassium phosphate buﬀer, pH 7.4). Then, 3.5 μg holo-enzyme was
added to 1 ml phosphate buﬀer with 500 µmol/L phenol and incubated
for 3 min at 37 °C in the presence of 150 µM arachidonate (AA), 1-
stearoly-2-arachidonyl-PE (SAPE) or both. The reaction was stopped
using ice-cold lipid extraction solvent, and immediate extraction of
lipids, after addition of 5 ng DMPE internal standard. In some
experiments, 10 μM diethylenetriaminepentaacetic acid (DTPA) was
added just before holoCOX-1. 18:0a/DXA3-PE was analyzed using
reverse phase LC-MS/MS as described below.
2.3. Isolation of human platelets
Human blood donations were approved by the Cardiﬀ University
School of Medicine Ethics Committee and were with informed consent
(SMREC 12/37, SMREC 12/10), and according to the Declaration of
Helsinki. Exclusion criteria was a known sensitivity to aspirin. For
studies on isolated platelets, whole blood was collected from healthy
volunteers free from non-steroidal anti-inﬂammatory drugs for at least
14 days into acid-citrate-dextrose (ACD; 85 mmol/L trisodium citrate,
65 mmol/L citric acid, 100 mmol/L glucose) (blood:ACD, 8.1:1.9, v/v)
and centrifuged at 250g for 10 min at room temperature. Platelet-rich
plasma was collected and centrifuged at 900g for 10 min, and the pellet
resuspended in Tyrode's buﬀer (134 mmol/L NaCl, 12 mmol/L
NaHCO3, 2.9 mmol/L KCl, 0.34 mmol/L Na2HPO4, 1.0 mmol/L
MgCl2,10 mmol/L Hepes, 5 mmol/L glucose, pH 7.4) containing ACD
(9:1, v/v). Platelets were centrifuged at 800g for 10 min then resus-
pended in Tyrode's buﬀer at 2×108 ml−1. Platelets were activated at
37 °C in the presence of 1 mmol/L CaCl2 for varying times, with
0.2 U ml−1 thrombin, 10 μg/ml collagen, 10 μmol/L A23187, 20 μmol/
L TFLLR-NH2, or 150 μmol/L AY-NH2 before lipid extraction as below.
Experiments involving signaling inhibitors included a 10 min preincu-
bation at room temperature. In some experiments, calcium was
omitted from buﬀers. For separation of cells from microparticles,
platelets were centrifuged at 970g for 5 min, then supernatants re-
spun at 16,060g for 5 min. For aspirin supplementation, blood samples
were ﬁrst obtained following a 14-day NSAID-free period for baseline
determinations of eicosanoids. Subjects were administered 75 mg/day
aspirin for 7 days, then provided a second blood sample. Platelets were
isolated and activated in vitro using 0.2 U/ml thrombin, as described
above, then lipids extracted as described below.
2.4. Clot isolation
Blood was allowed to clot for 1 h at 24 °C, and spun at 1730g for
10 min. Clot samples were placed in a pre-frozen mortar and pestle on
dry ice and further cooled with liquid nitrogen. 250 mg clot was ground
up in 3 ml PBS pH 7.4 containing 10 mM DTPA. Lipids were extracted
from 1 ml samples using the method below.
2.5. Lipid extraction
Lipids were extracted by adding a solvent mixture (1 mol/L acetic
acid, isopropyl alcohol, hexane (2:20:30, v/v/v)) to the sample at a
ratio of 2.5–1 ml sample, vortexing, and then adding 2.5 ml of hexane
[11]. Where quantitation was required, 5–10 ng PGE2-d4, and di-14:0-
phosphatidylethanolamine (DMPE) were added to samples before
extraction, as internal standards. After vortexing and centrifugation,
lipids were recovered in the upper hexane layer. The samples were then
re-extracted by addition of an equal volume of hexane. The combined
hexane layers were dried and analyzed for free or esteriﬁed PGs using
LC-MS/MS as below.
2.5.1. Reversed phase LC-MS/MS and LC/MS3 of esteriﬁed DXA3
For MRM analysis, lipids were separated on a C18 Luna, 3 µm,
150 mm×2 mm column (Phenomenex), using a gradient of 50–100% B
over 10 min followed by 30 min at 100% B (Solvent A: methanol:ace-
tonitrile:water, 1 mM ammonium acetate, 60:20:20. Solvent B: metha-
nol, 1 mM ammonium acetate) with a ﬂow rate of 200 μl/min.
Esteriﬁed DXA3 was monitored on a 4000 Q-Trap (Sciex) as precursors
of m/z 770.6, 796.6, 798.6 and 814.7 fragmenting to product ions at
m/z 351.2. For high resolution analysis, a reversed-phase UPLC
Fourier Transform MS method was used (Thermo Scientiﬁc Orbitrap
Elite). Analysis was performed using heated electrospray ionization (h-
ESI) in negative ion mode at sheet, auxiliary and sweep gas ﬂows of 70,
20, and 0, and capillary and source heater temperatures at 300 and
350 °C, respectively. Data dependent MS3 of m/z 351 from esteriﬁed
DXA3 was carried out in negative FTMS mode with a resolving power of
15,000. Lipid extracts were separated on a C18 Hypersil Gold, 1.9 µm,
100×2.1 mm column using a gradient (A, methanol/acetonitrile/water
containing 1 mM ammonium acetate, at a ratio 60:20:20; B, methanol,
1 mM ammonium acetate) with ﬂow rate 200 μl min –1, starting at 50%
B and maintaining for 10 min. The gradient increased to 100% B over
15 min and returning to initial conditions for 5 min. Orbitrap analysis
was performed using heated electrospray ionization (h-ESI) in negative
ion mode at sheath, auxiliary, and sweep gas ﬂows of 30, 10, and 0,
respectively. Capillary and source heater temperatures were 275 and
250 °C, respectively, at 30,000 resolution, in full scan mode. LC/MS of
precursor ions were monitored using accurate mass in FTMS mode.
Negative MS/MS spectra were acquired using higher energy collision-
induced-dissociation (HCD). Data dependent MS3 of m/z 351 was
carried out in ITMS mode on the LTQ Ion Trap. Where fold changes are
presented, data are shown as A/IS: analyte divided by internal
standard.
2.5.2. Phospholipase A2 Hydrolysis of esteriﬁed DXA3 and
quantitation of free acid form
PE was puriﬁed from thrombin-activated platelet lipid extracts
using normal phase HPLC as follows: extracts resuspended in normal
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phase solvents (50:50 of solvents A:B (A, hexane: propan-2-ol, 3:2; B,
solvent A:water, 94.5:5.5)) were separated on a Spherisorb S5W
4.6×150-mm column (Waters Ltd., Estree, Hertfordshire, UK) using
a gradient of 50–100% B over 25 min at a ﬂow rate of 1.5 ml min−1
[12]. Absorbance was monitored at 205 nm and products identiﬁed by
retention time comparison using a mixture of standard phospholipids
(bovine brain PC and PE, 25 mg/ml). Fractions were collected at 30 s
intervals and analyzed by direct ﬂow injection, for subsequent analysis
by ESI/MS/MS. Flow injection analysis of esteriﬁed DXA3s was
performed by injecting 20 μl of each fraction under ﬂow (1 ml min−1)
in methanol into the electrospray source, with speciﬁc MRM transi-
tions monitored using m/z 351 as the product ion, on a 4000 Q-trap.
PE fractions were dried using N2, then resuspended in 1 ml buﬀer
(150 mmol/L NaCl, 5 mmol/L CaCl2, 10 mmol/L Tris (Trizma base),
pH 8.9). 200 μg snake venom phospholipase A2 (PLA2) from Sigma-
Aldrich was added, and incubated for 60 min at 37 °C. Lipids were re-
extracted as above, using hexane:isopropanol:acetic acid. As a puriﬁed
standard is not yet available, we synthesized and puriﬁed a biogenic
standard using COX-1 (Hinz et al., in review). Quantitation was
achieved using PGE-d4 as internal standard. For analysis of free
DXA3, the following HPLC conditions were used: C18 Spherisorb
ODS2, 5 µm particle size, 150×4.6 mm (Waters Ltd., Elstree,
Hertfordshire, UK) on a Sciex 4000 Q-Trap. The solvent system was
75% water, 25% acetonitrile, 1% glacial acetic acid Solvent A, 60%
methanol, 40% acetonitrile, 1% glacial acetic acid at 1 ml min−1 Solvent
B. Solvent B was increased from 50–90% over 20 min and at 25 min
returned to 50% [13].
2.6. Isolation of DXA3-PEs from platelet lipid extracts
Washed human platelets were activated using A23187 (10 μM,
30 min, 37 °C) with 1 mM CaCl2 followed by lipid extraction. DXA3-
PEs were isolated using a Discovery C18 HPLC column
(25 cm×4.6 mm, 5 µm particle size (Sulpeco)) at 1 ml min−1, and 50–
100% mobile phase B (A: water, 2.5 mM ammonium acetate, B:
methanol, 1 mM ammonium acetate) over 15 min, held at 100% B
for 20 min. Fractions were collected at 1 min intervals then analyzed
using LC-MS/MS. DXA3-PE containing fractions were combined and
evaporated to dryness using a Rapidvap N2/48 evaporation system
(Labconco Corporation), resuspended in methanol, then stored at
−80 °C until use.
2.7. Isolation and activation of human neutrophils
Human neutrophils were isolated from 20 ml citrate anticoagulated
whole blood, and resuspended in Krebs buﬀer. Brieﬂy, blood was mixed
1:3 with 2% trisodium citrate (wt/vol) and HetaSep (Stemcell technol-
ogies) and allowed to sediment for 45 min at 20 °C. The upper plasma
layer was recovered and under laid with ice-cold Lymphoprep (2:1 for
plasma/Lymphoprep) and centrifuged at 800g for 20 min at 4 °C. The
pellet was resuspended in ice-cold PBS and 0.4% sodium tricitrate (wt/
vol) and centrifuged at 400g for 5 min at 4 °C. Contaminating
erythrocytes were removed using up to three cycles of hypotonic lysis.
Finally, cells were resuspended in a small volume of Krebs buﬀer
(100 mmol/L NaCl, 50 mmol/L HEPES, 5 mmol/L KCl, 1 mmol/L
MgCl2, 1 mmol/L NaH2PO4, 1 mmol/L CaCl2, and 2 mmol/L D-glu-
cose, pH 7.4), counted and kept on ice. Neutrophils were diluted to
2×106 cells/ml and incubated with or without HPLC puriﬁed DXA3-PE
(equivalent to lipids from 2×108 platelets/ml), vehicle (methanol or
DMSO), 1 μM 1-stearoyl-2-arachidonyl-PE (SAPE), or 1 μM fMLP for
20 min at 37 °C. In some experiments, neutrophils were pre-treated
with 1.60 µM U-75302 (Cayman Chemicals) or 1 µM LY255283
(Sigma-Aldrich) for 10 min at room temperature. Cells were blocked
using 5% mouse serum in PBS (containing 0.5% BSA, 5 mmol/L EDTA
and 2 mmol/L sodium azide) for 1 h on ice and centrifuged at 320g for
5 min at 4 °C. Anti-human CD11b-Alexa Fluor 647 (0.0625 μg,
BioLegend) or isotype control were added and incubated for 30 min
on ice. Neutrophils were washed twice with ice-cold PBS (containing
0.5% BSA, 5 mmol/L EDTA and 2 mmol/L sodium azide) and analyzed
on a Cyan ADP ﬂow cytometer (Beckman) and identiﬁed by forward
and side scatter and Alexa Fluor 647.
2.8. Statistics
Data on platelets are representative of at least three separate
donors, with samples run in triplicate for each experiment. Data are
expressed as mean ± SEM, of three separate determinations. Statistical
signiﬁcance was assessed using an unpaired, two-tailed Students t-test.
Where the diﬀerence between more than two sets of data was analyzed,
one-way ANOVA was used followed by Bonferroni multiple compar-
isons test, as indicated on legends. p < 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Human platelets generate phospholipid-esteriﬁed DXA3 on acute
activation
Previously we used precursor LC-MS/MS to screen for parents of
m/z 351.2 in lipid extracts from thrombin-activated platelets, in order
to ﬁnd esteriﬁed prostaglandins. This demonstrated several series of
ions consistent with four phosphatidylethanolamine (PE) species,
namely 16:0p, 18:1p, 18:0p and 18:0a-PE, where p refers to plasmalo-
gen and a to acyl, for the sn1 fatty acid [2]. Early eluting peaks were
identiﬁed as esteriﬁed PGE2/D2, but others remained uncharacterised.
Herein, a later eluting series are identiﬁed as DXA3-PEs using MS/MS
and MS3 both for the esteriﬁed forms and following cPLA2 hydrolysis of
puriﬁed platelet PE fractions (Figs. 1,2).
Using precursor to product m/z 351.2 in multiple reaction mon-
itoring (MRM) mode, two lipids were detected for each PE parent ion
(Fig. 1A-D). However, when analyzed using high resolution Orbitrap
MS, monitoring exact m/z, three lipids were seen (Fig. 1E-H). The ﬁrst
in each MS chromatogram represents co-eluting PGE2/D2-PEs
(Fig. 1E-H) [2]. These are not detected in MS/MS mode since PGE2
and D2 do not survive as intact carboxylate anions during collision-
induced-dissociation of their PE analogs (Fig. 1A-D) [2].
MS/MS of the third lipid in each series (marked with * in Fig. 1 A-
D) demonstrated similar product ions for all four parent PEs, and
several were consistent with DXA3, notably ions at m/z 149, 163 and
165 (Fig. 1I-L). A large product ion at m/z 283.2 was also detected for
m/z 814.5, indicating 18:0a (Fig. 1L). Neutral loss ions at m/z
corresponding to [M-352]- and [M-334]- were seen in all spectra for
loss of DXA3 and the DXA3 ketene, respectively. MS
3 of the m/z
351.2 ion from all four PEs conﬁrmed the structure of the lipid as
DXA3 (Fig. 2A-D) [1]. This showed characteristic product ions,
including prominent ones at m/z 163, 165, and also 207, 225 and
271. To further prove DXA3 was attached to PE, the lipids were puriﬁed
using HPLC, then saponiﬁed using snake venom PLA2, as described in
Materials and Methods. Analysis of saponiﬁed PE using the m/z 351.2
→ 271.2 showed some PGE2 and D2 at 32.6 and 34.7 min respectively,
however DXA3 was seen at 51.5 min, with MS/MS conﬁrming its
structure (Fig. 2E,F). To quantify DXA3 attached to PE, free DXA3 in
lipid extracts derived from thrombin-activated platelets was quantiﬁed
before and after hydrolysis using snake venom PLA2 (Fig. 3A). Total
esteriﬁed DXA3 in platelets from four donors was determined to be
24.3 ± 6.1 out of 31.6 ± 8.1 ng /2×108 platelets/ml (mean ± SEM). This
indicates that the majority of DXA3 is esteriﬁed, with structural data
conﬁrming the four lipids as 16:0p/DXA3-PE, 18:1p/DXA3-PE, 18:0p/
DXA3-PE and 18:0a/DXA3-PE.
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3.2. Characterization of platelet signaling pathways involved in
DXA3-PE generation
On platelet activation, DXA3-PE was generated early, in particular
in response to thrombin where it plateaued after 10 min (Fig. 3B-D).
DXA3-PE was retained by the cells, in contrast to free DXA3, which is
primarily secreted, indicating that the two forms partition diﬀerently
(Fig. 3E,F). DXA3-PE formation required PLC, but not PI3 kinase,
while inhibition of PKC signiﬁcantly increased DXA3-PE generation
(Fig. 4A,B). The negative control (U-73373) for the PLC inhibitor (U-
73112) showed approximately 50% inhibition, but far less than seen
using U-73112 (Fig. 4A). This suggests some oﬀ target eﬀects of U-
73112, but supports PLC involvement in DXA3-PE generation.
Formation of DXA3-PEs was dependent on intracellular but not
extracellular calcium (Fig. 4C). An essential role for COX-1 was
revealed through either in vivo (7 days of 75 mg/day aspirin) or in
vitro inhibition (SC-560, aspirin, indomethacin) inhibition (Fig. 4D-F),
while cPLA2 but not iPLA2 or sPLA2 was also required (Fig. 5A,B). Last,
formation of DXA3-PE was triggered via PAR-1 and −4 receptors
(Fig. 5C). Notably, the timescale for formation of esteriﬁed DXA3 is
Fig. 1. Identiﬁcation and MS/MS fragmentation of esteriﬁed DXA3-PE generated by human platelets. Panels A-D. Lipidomic identiﬁcation of esteriﬁed DXA3. Lipid extracts from
thrombin-activated platelets (0.2 U/ml, 30 min) were separated using reverse phase LC-MS/MS on a Luna column, monitoring precursor to m/z 351.2 for: Panel A: 770.6, Panel B:
796.6, Panel C: 798.6 and Panel D: 814.7. The second eluting lipid marked with * was identiﬁed as DXA3-PE. Panels E-H. High resolution LC/MS analysis of DXA3-PEs. Platelet lipid
extracts were analyzed using an Orbitrap Elite, with a Hypersil Gold column, in full scan mode at 30,000 resolution. Extraction ion chromatograms corresponding to precursor m/z
770.4978, 796.5134, 798.5291 and 814.5240 are shown, with DXA3-PE labeled by arrow. Panels I-L. High resolution LC-MS/MS spectra of DXA3-PEs. Data-dependent LC-MS/MS
spectra were acquired using higher energy collision-induced dissociation (HCD) fragmentation, with Orbitrap detection.
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very similar to that of the free acid form with a fast generation within
the ﬁrst 10 min of activation [1].
3.3. Enzymatic mechanism of DXA3-PE formation by COX-1
DXA3-PE could form via direct PE oxidation or via oxidation of AA
released by cPLA2 followed by esteriﬁcation into PE. The latter is more
likely since COX-1 is unable to directly oxidize complex lipids, and
DXA3-PE formation was sensitive to cPLA2 inhibition. In support,
thimerosal, an inhibitor of lysophospholipid acyl transferases (LPAT)
elevated free DXA3, while suppressing DXA3-PE formation (Fig. 5D,E).
This supports a mechanism whereby AA is hydrolyzed by cPLA2,
oxidized by COX-1 to DXA3, then re-esteriﬁed into PE via LPAT
enzymes. Triascin C, an inhibitor of fatty acyl Co-A ligase (FACL),
inhibited formation of DXA3-PE, but also partially blocked free DXA3
formation (Fig. 5F,G). COX-1 is generally considered unable to oxidize
complex substrates. To conﬁrm this, we incubated 18:0a/20:4-PE with
COX-1. Hematin controls showed a small oxidation to form DXA3-PE,
but this was not increased by inclusion of COX-1 (Fig. 6A,B). However,
when AA was added, allowing COX-1 turnover, additional DXA3-PE
was formed. As this was not sensitive to metal chelation, it likely results
from secondary oxidation directly mediated by lipid radicals that
escape the active site of COX-1 during turnover (Fig. 6A,B). We note
that thimerosal blocked approx. 50% of the generation of DXA3-PEs
(Fig. 5D). Thus, at least half of these lipids form in platelets via
esteriﬁcation, rather than radical-mediated oxidation.
3.4. DXA3-PE from human platelets activates human neutrophil
integrin expression
DXA3-PE was isolated from activated platelet lipid extracts using
HPLC. When added at concentrations approximating a physiological
platelet concentration (equivalent to 2×108 cells/ml), neutrophil Mac-
1 expression increased signiﬁcantly (Fig. 6D,E). In contrast, the
Fig. 2. MS3 of DXA3-PEs, and its hydrolysis from puriﬁed PE fractions further conﬁrms structure. Panels A-D. LC/MS
3 of DXA3-PE conﬁrms ions that originate from m/z 351.2. Data
dependent LC/MS3 spectra were acquired in ITMS mode on the Orbitrap platform using collision-induced dissociation, with precursor to m/z 351.2 as product ion. Panels E. DXA3 is
released from platelet PE on hydrolysis. PE was puriﬁed from lipids extracted from ionophore activated platelets, then analyzed for free DXA3 using LC-MS/MS (m/z 351.2-271.2)
before (solid line) or after (dashed line) hydrolysis using snake venom PLA2, as described in Methods. LC-MS/MS was undertaken on the 4000 Q-Trap, as described for free DXA3. Panel
F. MS/MS spectrum conﬁrming the lipid eluting at 51.5 min as DXA3. Data dependent LC-MS/MS was undertaken during elution of the lipid at 51.5 min as described in Methods.
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unoxidized analog, 1-stearoyl-2-arachidonyl-PE (SAPE) did not acti-
vate Mac-1 (Fig. 6D). When incubated for 30 min with neutrophils, no
loss of DXA3-PE was seen, nor was free DXA3 generated (Fig. 6F). This
indicates that hydrolysis of DXA3-PE by neutrophil phospholipases did
not occur and indicating that Mac-1 activation is stimulated directly by
the esteriﬁed form. Instead, levels of DXA3-PE appeared to slightly
increase, likely a matrix eﬀect on extraction from the presence of
neutrophil lipids and proteins. Last, to explore the signaling mechan-
isms, antagonists of leukotriene B4 receptors, BLT1 and BLT2 were
included. However, neither prevented the expression of Mac-1 indicat-
ing that DXA3-PE activates neutrophils by BLT receptor-independent
mechanisms (Fig. 6G).
4. Discussion
Recent studies identiﬁed a platelet lipid, DXA3 that forms via
enzymatic oxidation of AA by COX-1 in response to physiological
agonist activation. This lipid primes and activates human neutrophils
at nM-μM concentrations in vitro suggesting its likely importance in
innate immune responses [1]. In that study, only the free acid lipid was
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described. Herein, we demonstrate that the majority of DXA3 is initially
formed esteriﬁed to four PEs, remains cell-associated and is generated
in human clots in vitro. Like the free acid analog, DXA3-PE also
activates neutrophils at physiologically-relevant concentrations. The
study adds to the growing evidence that enzymatic phospholipid
oxidation by platelets is a physiological process that occurs during
blood clotting and hemostasis and modulates innate immunity [3].
DXA3-PE is formed on a similar timescale, within 2–10 min post
agonist activation, as free DXA3 (Fig. 3 B-D) and entirely from
endogenous substrate mobilized during physiological platelet activa-
Fig. 4. DXA3-PE formation requires the activity of PLC, calcium, cPLA2 and COX-1, and occurs via esteriﬁcation of free DXA3. Panels A-C Eﬀects of signaling inhibitors on DXA3
formation. Platelets were incubated with inhibitors 10 min prior to thrombin activation (0.2 U/ml for 30 min at 37 °C). Lipids were extracted and analyzed using LC-MS/MS monitoring
precursor [M-H]- m/z 351.2 → 165.1, as described in Methods. Data are representative of experiments repeated at least three times on diﬀerent donors (n=3, mean ± SEM). *** P <
0.001 versus thrombin, using ANOVA and Bonferroni Post Hoc Test. Panel A. U-73112, 10 µM (PLC), or its negative control U-73343. Panel B. wortmannin, 100 nM (PI3 kinase), Gö
6850 (protein kinase C), 100 nM (PKC) or vehicle (DMSO, 0.5%), Panel C. EGTA 1 mM (extracellular Ca2+) or BAPTA-AM 10 mM (intracellular Ca2+). Panels D,E. Generation of DXA3-
PE is sensitive to COX inhibition in vitro. Platelets were incubated with 1 mM aspirin, 1 μM SC-560 or 10 μM indomethacin prior to thrombin activation (0.2 U/ml for 30 min at 37 °C).
Lipids were extracted and analyzed as described in Methods. Levels are expressed as ratio analyte to internal standard. Data are representative of experiments repeated at least three
times on diﬀerent donors (n=3, mean ± SEM). Panel F. In vivo aspirin supplementation blocks generation of DXA3-PE. Lipids were analyzed following thrombin activation of washed
platelets, before or after supplementation with 75 mg/day aspirin for 7 days. Data are representative of ﬁve independent donors (n=5, mean ± SEM); ***p < 0.001 versus thrombin
alone, using ANOVA and Bonferroni Post Hoc Test. Levels of DXA3-PEs are expressed as ratio analyte to internal standard. A/IS: analyte:internal standard.
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tion [1]. This indicates that a controlled enzymatic formation, similar
to the generation of HETE-PEs by platelet 12-lipoxygenase (LOX),
macrophage 12/15-LOX and neutrophil 5-LOX. Pharmacological stu-
dies indicated involvement of PLC, intracellular calcium, cPLA2 and
COX-1 [3, 5, 11]. These signaling mediators are also required for free
DXA3 formation demonstrating that PE-esteriﬁed forms require ﬁrst
the generation of the free acid form [1]. This was further supported by
observations that an inhibitor of LPAT signiﬁcantly blocked their
formation (Fig. 5D,E). Activation by PAR agonists suggests the
involvement of these receptors in thrombin activation, however
thrombin can also activate additional receptors, including integrins.
Platelets express several PKC isoforms, of which some promote and
Fig. 5. DXA3-PE generation requires cPLA2, PAR receptors and LPAT but not other PLA2 isoforms. Panel A. Inhibition of DXA3-PE generation by cPLA2 blockade. Platelets were
incubated with cPLA2i 50 nM (cPLA2 inhibitor) prior to thrombin activation (0.2 U/ml for 30 min at 37 °C). Lipids were extracted and analyzed as described in Methods. Levels are
expressed as ratio analyte to internal standard. Data are representative of experiments repeated at least three times on diﬀerent donors (n=3, mean ± SEM). Panel B. Formation of
DXA3-PE does not require iPLA2 or sPLA2. DXA3-PE formation by platelets incubated with 2 µM OOEPC (sPLA2), 50 nM BEL (iPLA2) or vehicle (DMSO, 0.5%) before thrombin
activation was determined. Levels are expressed as analyte:internal standard. Panel C. DXA3-PE is generated via PAR-1 and PAR-4 receptor stimulation. Washed platelets were
activated with a PAR-1 agonist, TFLLR-NH2 (20 μM), and/or a PAR-4 agonist, AY-NH2 (150 μM), for 30 min at 37 °C then analyzed, as described in Methods. Panels D,E. Generation of
DXA3-PE is inhibited by thimerosal, while free DXA3 is enhanced. Washed platelets were incubated with 75 µM of thimerosal for 30 min at 37 °C prior to thrombin activation, before
lipid extraction and analysis. Panels F,G. Generation of free and esteriﬁed DXA3-PE is inhibited by triascin C. Washed platelets were incubated with 7 µM of triascin C for 30 min at
37 °C prior to thrombin activation, before lipid extraction and analysis. Levels are expressed as analyte:internal standard. Data are representative of experiments repeated at least three
times on diﬀerent donors (n=3, mean ± SEM). ***p < 0.001 versus thrombin, using ANOVA and Bonferroni Post Hoc Test. A/IS: analyte:internal standard.
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others inhibit platelet activation. For example, PKCα can be pro- while
PKCδ can be anti-aggregatory [14]. Go6850 (at 100 nM) will inhibit a
number of PKC isoforms, including α,β,δ and ε [15]. We found that this
enhanced generation of DXA3-PE suggesting that overall, PKC isoforms
are suppressing this pathway. Using puriﬁed COX-1, we showed that
COX-1 does not directly oxidize 18:0a/20:4-PE (Fig. 6A). However, a
small amount of co-oxidation could be mediated during AA oxidation.
This suggests an additional route to DXA3-PE formation and could
account for the thimerosal-insensitive generation seen in platelets
(Fig. 5D), however it is likely that non-enzymatic routes to synthesis
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Panel F. Neutrophils do not hydrolyze DXA3-PE. Neutrophils (2×106/ml) were incubated with DXA3-PE for 30 min at 37°, before lipid extraction and analysis using LC/MS/MS as
described in Methods. Free DXA3 was not detected under these conditions. Panel G. DXA3-PE activation of Mac-1 is independent of BLT1 and BLT2. Neutrophils were incubated with/
without DXA3-PE as described in Methods, with pretreatment (10 min, 22 °C) with 1.6 mM U-75302 (BLT1 antagonist) or 1 mM LY255283 (BLT2 antagonist). Mac-1 expression was
determined using CD11b-Alexa Fluor 647 detected by ﬂow cytometry, n=3, mean ± SEM, ANOVA with Bonferroni Post Hoc Test. *** p < 0.001.
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would be tightly controlled and minimized in platelets via the action of
glutathione peroxidases.
The majority of DXA3 is detected as esteriﬁed to PE in platelets
(Fig. 3A). This contrasts with HETE-PEs of which only 30% is attached
to phospholipids, and TXB2 which has not been found to occur in
esteriﬁed forms, and suggests that esteriﬁcation pathways may favor
certain oxidized lipids, but this remains to be fully investigated [3].
Recently, we used lipidomics to proﬁle oxidized PL generated by
human platelets and found over 100 species all generated on acute
activation with thrombin [4]. One family, HETE-PEs, can translocate to
the outside of the plasma membrane and is prothrombotic in vitro,
raising the possibility that membrane PL oxidation is a general
phenomenon that regulates innate immune events during acute injury
[3].
Herein, DXA3-PE was found to activate neutrophil Mac-1 expres-
sion, independently of hydrolysis to free DXA3 (Fig. 6D-H). This
indicates that DXA3 could potentially act either as a soluble mediator
when free, or alternatively when remaining cell-associated, if facing out
of the membrane surface and attached to PE (e.g. during platelet-
neutrophil interactions). This would be a new concept for eicosanoid
signaling, since traditionally these were only thought of as soluble
signaling agents. Previous, eicosanoids were not considered to be re-
esteriﬁed into phospholipids in signiﬁcant amounts. This study show-
ing DXA3 esteriﬁcation strengthens previous reports of formation of
PGE2- and HETE-PE formation as a regulated biological process
[2,3,5,6,11,16].
We suspected that DXA3-PE might activate LTB4 receptors, either
BLT1 or BLT2, since both are present in neutrophils and known to
upregulate Mac-1 expression [17,18]. However, both were excluded
using receptor antagonists (Fig. 6H). Neutrophils express many cell
surface receptors, including other G protein coupled receptors, Toll-
like receptors and integrins [17]. Thus DXA3-PE likely activates other
pathways to upregulate Mac-1 expression and further studies are
required to delineate this. Indeed whether the free and esteriﬁed forms
of this lipid can also stimulate additional neutrophil activities including
calcium mobilization, superoxide generation and degranulation, also
will be determined.
Neutrophil phospholipids that have incorporated exogenous eico-
sanoids can be subsequently hydrolyzed by secondary cell stimulation,
for example releasing free acid 15-HETE [19]. Thus, during blood
clotting, phospholipases such as sPLA2 could metabolise DXA3-PEs
from activated platelets generating the free acid analog and thus
further supporting innate immune responses to acute injury via soluble
diﬀusion, with this lipid able to signal either in free or esteriﬁed forms.
In summary, DXA3-PEs represent new platelet lipids generated
through receptor-regulated cell signaling pathways. The full structural
characterization of DXA3 and generation of synthetic standards will
enable further study of its functions in innate immunity.
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